US Archives - Page 69 of 129 - European Medical Journal

Positive Survival Outcomes for Melanoma Brain Metastases in New Trial

A phase II trial evaluating the combination of pembrolizumab and bevacizumab in patients with untreated melanoma brain metastases (MBM) has demonstrated substantial clinical activity and promising survival outcomes.

Can AI Diagnose Unexplained Fainting?

A machine-learning classifier designed to assist healthcare professionals in accurately diagnosing the causes of transient loss of consciousness (TLOC) has been introduced in a new study.

Pediatric OSA: How Predictive is CPAP Pressure?

Continuous positive airway pressure (CPAP) therapy is a cornerstone in managing severe obstructive sleep apnea (OSA) in children.

AI Predicts Tuberculosis Risk in HIV: CROI 2025

A machine learning-based model has demonstrated the ability to predict active tuberculosis (TB) in people with HIV (PWH) using clinical data, offering a promising tool for improving early detection and preventive treatment.

Are We Testing the Right Patients for TB? Data from CROI 2025

New data from a 15-year study presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco reveals significant disparities in latent tuberculosis infection (LTBI) testing practices within the United States.

Streamlined Self-Efficacy Measure Enhances ART Outcomes: CROI 2025

A recent study presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco has unveiled a simplified approach to assessing antiretroviral therapy (ART) adherence among pregnant women living with HIV in Malawi.

New Long-Term Solution for Chronic Hand Eczema

A recent phase 3 open-label extension study has demonstrated that delgocitinib cream is both safe and effective for long-term management of chronic hand eczema (CHE) in adults.

Comparing Immunosuppressants: What Works Best in Systemic Sclerosis?

A recent analysis from the RESOLVE-1 trial has highlighted the potential of mycophenolate mofetil (MMF) in treating diffuse cutaneous systemic sclerosis (dcSSc), particularly in early-stage disease.

Remdesivir and COVID-19: Are Treatment Guidelines Keeping Up?

A new systematic review and meta-analysis of over 1.3 million patients has confirmed that remdesivir significantly improves survival rates for hospitalized COVID-19 patients, yet treatment guidelines may not fully reflect this evolving evidence.

Why Diversity in Clinical Trials Matters More Than Ever

Increasing diversity in research, from basic science to clinical trials, remains essential for advancing equitable healthcare outcomes.